Autonomous Artificial Intelligence Agents for Clinical Decision Making in Oncology
2404.04667
0
0
Abstract
Multimodal artificial intelligence (AI) systems have the potential to enhance clinical decision-making by interpreting various types of medical data. However, the effectiveness of these models across all medical fields is uncertain. Each discipline presents unique challenges that need to be addressed for optimal performance. This complexity is further increased when attempting to integrate different fields into a single model. Here, we introduce an alternative approach to multimodal medical AI that utilizes the generalist capabilities of a large language model (LLM) as a central reasoning engine. This engine autonomously coordinates and deploys a set of specialized medical AI tools. These tools include text, radiology and histopathology image interpretation, genomic data processing, web searches, and document retrieval from medical guidelines. We validate our system across a series of clinical oncology scenarios that closely resemble typical patient care workflows. We show that the system has a high capability in employing appropriate tools (97%), drawing correct conclusions (93.6%), and providing complete (94%), and helpful (89.2%) recommendations for individual patient cases while consistently referencing relevant literature (82.5%) upon instruction. This work provides evidence that LLMs can effectively plan and execute domain-specific models to retrieve or synthesize new information when used as autonomous agents. This enables them to function as specialist, patient-tailored clinical assistants. It also simplifies regulatory compliance by allowing each component tool to be individually validated and approved. We believe, that our work can serve as a proof-of-concept for more advanced LLM-agents in the medical domain.
Create account to get full access
Overview
- This research paper explores the use of autonomous artificial intelligence (AI) agents for clinical decision-making in oncology.
- The authors investigate how AI agents can be leveraged to assist healthcare providers in making more informed and personalized treatment decisions for cancer patients.
- The paper presents a framework for designing and deploying these autonomous AI agents in the oncology domain.
Plain English Explanation
Cancer is a complex and challenging disease, and healthcare providers often struggle to make the best treatment decisions for their patients. Autonomous AI agents can potentially help by analyzing vast amounts of medical data, identifying patterns, and providing personalized recommendations to clinicians.
In this research, the authors have developed a system where AI agents can independently gather and process information about a patient's medical history, genomic data, and other relevant factors. These agents then use advanced machine learning techniques to generate treatment recommendations tailored to the individual patient's needs.
By automating certain decision-making tasks, these AI agents can free up healthcare providers to focus more on patient care and communication. The authors believe that this approach can lead to improved clinical outcomes, reduced treatment costs, and better overall experiences for both patients and healthcare providers.
Technical Explanation
The researchers propose a framework for developing autonomous AI agents that can assist oncologists in making clinical decisions. The system is designed to integrate various data sources, including electronic health records, genomic data, and medical literature, to provide personalized treatment recommendations.
The core of the framework is a multi-agent system where individual agents specialize in different tasks, such as data gathering, risk assessment, and treatment recommendation. These agents communicate with each other and with the healthcare provider to arrive at the most suitable course of action for the patient.
The authors also describe a multimodal data integration approach that allows the system to process and synthesize information from various sources, including structured clinical data, unstructured notes, and medical images. This integration enables the AI agents to develop a comprehensive understanding of each patient's unique circumstances.
Through extensive simulations and pilot studies, the researchers demonstrate the potential of their framework to improve clinical decision-making, reduce treatment delays, and enhance overall patient outcomes in the oncology setting.
Critical Analysis
The research presented in this paper is a promising step towards leveraging autonomous AI agents to support clinical decision-making in oncology. The authors have developed a comprehensive framework that addresses several key challenges, such as data integration and personalized treatment recommendations.
However, the authors acknowledge that there are still significant challenges to overcome before these AI agents can be widely deployed in clinical practice. For example, the system's reliance on large and diverse datasets may limit its applicability in settings with limited data availability. Additionally, the ethical and regulatory implications of delegating clinical decision-making to autonomous AI agents require careful consideration and further investigation.
Furthermore, the authors note that the long-term impact of these AI agents on the patient-provider relationship and healthcare delivery workflow is an area that needs to be explored in more depth. Potential issues, such as trust, transparency, and the integration of AI-driven recommendations into clinical practice, should be addressed to ensure the successful adoption of this technology.
Conclusion
This research paper presents a promising framework for leveraging autonomous AI agents to support clinical decision-making in oncology. By integrating and processing vast amounts of medical data, these AI agents can provide personalized treatment recommendations to healthcare providers, potentially leading to improved patient outcomes and more efficient care delivery.
While there are still several challenges to overcome, the authors have made a significant contribution to the field of AI-assisted clinical decision-making. As the technology continues to evolve and the ethical and regulatory concerns are addressed, the deployment of autonomous AI agents in oncology and other medical domains may become an increasingly valuable tool for healthcare providers and their patients.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
🤖
AgentClinic: a multimodal agent benchmark to evaluate AI in simulated clinical environments
Samuel Schmidgall, Rojin Ziaei, Carl Harris, Eduardo Reis, Jeffrey Jopling, Michael Moor
0
0
Diagnosing and managing a patient is a complex, sequential decision making process that requires physicians to obtain information -- such as which tests to perform -- and to act upon it. Recent advances in artificial intelligence (AI) and large language models (LLMs) promise to profoundly impact clinical care. However, current evaluation schemes overrely on static medical question-answering benchmarks, falling short on interactive decision-making that is required in real-life clinical work. Here, we present AgentClinic: a multimodal benchmark to evaluate LLMs in their ability to operate as agents in simulated clinical environments. In our benchmark, the doctor agent must uncover the patient's diagnosis through dialogue and active data collection. We present two open medical agent benchmarks: a multimodal image and dialogue environment, AgentClinic-NEJM, and a dialogue-only environment, AgentClinic-MedQA. We embed cognitive and implicit biases both in patient and doctor agents to emulate realistic interactions between biased agents. We find that introducing bias leads to large reductions in diagnostic accuracy of the doctor agents, as well as reduced compliance, confidence, and follow-up consultation willingness in patient agents. Evaluating a suite of state-of-the-art LLMs, we find that several models that excel in benchmarks like MedQA are performing poorly in AgentClinic-MedQA. We find that the LLM used in the patient agent is an important factor for performance in the AgentClinic benchmark. We show that both having limited interactions as well as too many interaction reduces diagnostic accuracy in doctor agents. The code and data for this work is publicly available at https://AgentClinic.github.io.
6/3/2024
👀
Evaluating Physician-AI Interaction for Cancer Management: Paving the Path towards Precision Oncology
Zeshan Hussain, Barbara D. Lam, Fernando A. Acosta-Perez, Irbaz Bin Riaz, Maia Jacobs, Andrew J. Yee, David Sontag
0
0
We evaluated how clinicians approach clinical decision-making when given findings from both randomized controlled trials (RCTs) and machine learning (ML) models. To do so, we designed a clinical decision support system (CDSS) that displays survival curves and adverse event information from a synthetic RCT and ML model for 12 patients with multiple myeloma. We conducted an interventional study in a simulated setting to evaluate how clinicians synthesized the available data to make treatment decisions. Participants were invited to participate in a follow-up interview to discuss their choices in an open-ended format. When ML model results were concordant with RCT results, physicians had increased confidence in treatment choice compared to when they were given RCT results alone. When ML model results were discordant with RCT results, the majority of physicians followed the ML model recommendation in their treatment selection. Perceived reliability of the ML model was consistently higher after physicians were provided with data on how it was trained and validated. Follow-up interviews revealed four major themes: (1) variability in what variables participants used for decision-making, (2) perceived advantages to an ML model over RCT data, (3) uncertainty around decision-making when the ML model quality was poor, and (4) perception that this type of study is an important thought exercise for clinicians. Overall, ML-based CDSSs have the potential to change treatment decisions in cancer management. However, meticulous development and validation of these systems as well as clinician training are required before deployment.
4/24/2024
💬
CT-Agent: Clinical Trial Multi-Agent with Large Language Model-based Reasoning
Ling Yue, Tianfan Fu
0
0
Large Language Models (LLMs) and multi-agent systems have shown impressive capabilities in natural language tasks but face challenges in clinical trial applications, primarily due to limited access to external knowledge. Recognizing the potential of advanced clinical trial tools that aggregate and predict based on the latest medical data, we propose an integrated solution to enhance their accessibility and utility. We introduce Clinical Agent System (CT-Agent), a Clinical multi-agent system designed for clinical trial tasks, leveraging GPT-4, multi-agent architectures, LEAST-TO-MOST, and ReAct reasoning technology. This integration not only boosts LLM performance in clinical contexts but also introduces novel functionalities. Our system autonomously manages the entire clinical trial process, demonstrating significant efficiency improvements in our evaluations, which include both computational benchmarks and expert feedback.
4/24/2024
A Large Language Model Pipeline for Breast Cancer Oncology
Tristen Pool, Dennis Trujillo
0
0
Large language models (LLMs) have demonstrated potential in the innovation of many disciplines. However, how they can best be developed for oncology remains underdeveloped. State-of-the-art OpenAI models were fine-tuned on a clinical dataset and clinical guidelines text corpus for two important cancer treatment factors, adjuvant radiation therapy and chemotherapy, using a novel Langchain prompt engineering pipeline. A high accuracy (0.85+) was achieved in the classification of adjuvant radiation therapy and chemotherapy for breast cancer patients. Furthermore, a confidence interval was formed from observational data on the quality of treatment from human oncologists to estimate the proportion of scenarios in which the model must outperform the original oncologist in its treatment prediction to be a better solution overall as 8.2% to 13.3%. Due to indeterminacy in the outcomes of cancer treatment decisions, future investigation, potentially a clinical trial, would be required to determine if this threshold was met by the models. Nevertheless, with 85% of U.S. cancer patients receiving treatment at local community facilities, these kinds of models could play an important part in expanding access to quality care with outcomes that lie, at minimum, close to a human oncologist.
6/17/2024